# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Francois Brisebois maintains Achieve Life Sciences (NASDAQ:ACHV) with a Outperform and lowers the price ...
Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate ...
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo...
- SEC Filing
JonesTrading analyst Justin Walsh initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Buy rating and announces ...